[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"theta-burst-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:theta-burst-stimulation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,75,103,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100640850","explore-the-impacts-of-theta-burst-stimulation-over-the-right-inferior-frontal-gyrus-in-autism-spectrum-disorder-combination-of-clinical-symptoms-neuropsychological-function-and-mri-100640850",false,"NCT07579494","Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI","Inclusion Criteria:\n\n* Participants aged 8 to 30 years with a clinical diagnosis of Autism Spectrum Disorder (ASD), confirmed by the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition).\n* DSM-5 severity level of ASD: level 1 or level 2\n* Participants who have been on a stable treatment regimen prior to the study, or those for whom conventional treatments have been assessed as ineffective by a physician, or those who decline conventional treatment.\n* A score of ≥ 15 on the University of California Brief Assessment of Capacity to Consent (UBACC) and demonstrated understanding of study aims and risks via the teach-back method.\n\nExclusion Criteria:\n\n* Previous or current severe neurological disorders, especially epilepsy, visual or auditory impairments\n* Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension\n* Previous or current severe brain injury\n* Implementation of metal materials such as a pacemaker or medication pump\n* Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse\n* Pregnancy\n* Presence of significant brain abnormalities, such as intracranial space-occupying lesions\n* Previous brain surgery or central nerve system infection\n* Concurrent use of medications which increased the risk of seizure attack\n* Participate in another clinical trial within one month\n* With damaged skin at the stimulated region\n* With multiple sclerosis\n* With large ischemic scars\n* Have experienced sleep disorders during brain stimulation\n* Severe alcoholism\n* Concurrent use of antiepileptic drugs\n* Uncontrollable migraines due to increased intracranial pressure\n* Unsuitable for MRI (e.g. those with claustrophobia)\n* Unsuitable for EEG\n* DSM-5 severity level of ASD: level 3\n* Current major depressive disorder\n* Suicidal ideation within one year\n* Currently taking tricyclic antidepressants (TCAs), analgesics, or any medications known to lower the seizure threshold.\n\nWithdrawal Criteria:\n\n* Seizure attack during the study period\n* Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)\n* Extreme agitation or irritability during the study period\n* Participants request\n* Clinical symptoms worsened obviously during study period\n* Start to use antiepileptic drugs during study period\n* Suicidal ideation or self-harm behaviors during study period\n* Changes in the frequency or dosage of concurrent treatments during the study period.","ALL","8 Years","30 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.",[26,27,28],"Autism Spectrum Disorder","Theta Burst Stimulation","Right Inferior Frontal Gyrus","RECRUITING","2026-05-05",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":30,"type":33},{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"Chang Gung Memorial Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100626725","multifocal-theta-burst-stimulation-to-enhance-upper-limb-motor-recovery-after-stroke-inspire-100626725","NCT07439367","Multifocal Theta-Burst Stimulation to Enhance Upper Limb Motor Recovery After Stroke (INSPIRE)","Advancing Stroke Rehabilitation Through Multifocal Network-based Theta-burst Stimulation and Assistive Technology: Enhancing Upper Limb Motor Learning: A Single-center, Randomized, Sham-controlled Study With Parallel Groups.","INSPIRE","Inclusion Criteria:\n\nFor Stroke Participants:\n\n* Age ≥ 18 years\n* First-ever ischemic or hemorrhagic stroke\n* Time since stroke ≥ 6 months\n* Unilateral upper limb hemiparesis\n* Fugl-Meyer Assessment Upper Extremity (FMA-UE) score between 29 and 57\n* Modified Ashworth Scale score \\\u003C 2 at elbow, wrist, or finger flexors\n* Manual muscle testing ≥ 3\u002F5 in proximal upper limb muscles (deltoid, biceps, triceps, wrist pronators\u002Fsupinators)\n* Ability to understand and follow study procedures\n* Provided written informed consent\n\nFor Healthy Participants:\n\n* Age ≥ 18 years\n* No history of neurological disease\n* Ability to understand and follow study procedures\n* Provided written informed consent\n\nExclusion Criteria:\n\nFor Stroke Participants:\n\n* Second stroke occurring during the study period\n* Botulinum toxin injection within 3 months prior to study start\n* History of one or more epileptic seizures\n* Metallic object near the stimulation site\n* Implanted electronic or metallic devices (e.g., pacemaker, neurostimulator) incompatible with TMS\n* Severe comorbid conditions affecting the upper limb (traumatic, rheumatologic, osteoarticular, or neurodegenerative disorders)\n* Pregnancy\n* Delirium or impaired vigilance\n* Inability to participate in one-hour treatment sessions\n* Inability to comply with study procedures (e.g., language barrier, psychological disorder, dementia)\n* Current or past substance abuse, including excessive alcohol consumption\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n\nFor Healthy Participants:\n\n* Severe musculoskeletal or neurological condition affecting the non-dominant upper limb\n* Pregnancy\n* Delirium or impaired vigilance\n* Inability to participate in one-hour treatment sessions\n* Inability to comply with study procedures\n* Current or past substance abuse, including excessive alcohol consumption\n* Participation in another interventional clinical trial within 30 days prior to enrollment",true,"18 Years",{"count":52,"type":20},46,[23],"Stroke is one of the leading causes of long-term disability worldwide. Many individuals who survive a stroke continue to experience weakness and reduced control of one arm, even months or years after the event. These motor impairments significantly affect independence, daily activities, and quality of life. Despite rehabilitation efforts, recovery of upper limb function remains incomplete for many patients.\n\nMotor recovery after stroke depends on the brain's ability to reorganize itself, a process known as neuroplasticity. Recent research suggests that motor learning and brain recovery are influenced not only by activity in the primary motor cortex (M1), but also by its functional connectivity with other brain regions, particularly the parietal cortex (PC). Strengthening communication between these regions may enhance motor recovery.\n\nThis study aims to investigate a novel, non-invasive brain stimulation approach called intermittent theta-burst stimulation (iTBS). Unlike traditional stimulation methods that target a single brain region, this study uses a multifocal stimulation protocol targeting both the primary motor cortex and the parietal cortex. The stimulation is combined with structured motor training using an interactive tablet-based rehabilitation device (REAtouch®Lite 2), designed to improve arm movement through goal-directed reaching tasks.\n\nThe study is a single-center, randomized, sham-controlled, triple-blind clinical trial with parallel groups. Thirty-six individuals with chronic stroke-related upper limb impairment will be randomly assigned to receive either active multifocal iTBS or sham (placebo) stimulation. Both groups will complete identical motor training sessions. In addition, ten healthy participants will complete the same motor training protocol (without brain stimulation) to provide reference data.\n\nParticipants will attend six visits over approximately 10 days. Assessments will include motor performance tests using the interactive tablet, a standardized clinical motor scale (Fugl-Meyer Assessment for Upper Extremity), and resting-state electroencephalography (EEG) to measure brain connectivity changes.\n\nThe primary outcome is improvement in motor performance between baseline and one week after the intervention. Secondary outcomes include short-term motor improvements, retention of learning, changes in movement quality, and changes in brain functional connectivity.\n\nThis study seeks to determine whether combining multifocal brain stimulation with targeted motor training can enhance motor learning and promote better recovery of arm function after stroke. If effective, this approach could contribute to the development of more precise, network-based neurorehabilitation strategies.",[56,57,58,27],"Chronic Stroke Patient","Motor Impairment","Neurorehabilitation",[60,61,62,63,64,65],"Chronic Stroke","Upper Limb Rehabilitation","Intermittent Theta Burst Stimulation","Tablet-Based Rehabilitation","Neuroplasticity","Motor Learning","2026-02-23",{"date":68,"type":33},"2026-02-27",{"date":70,"type":33},"2025-09-05",{"date":72,"type":20},"2026-08-31",{"name":74,"class":39},"School of Health Sciences Geneva",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100617268","repetitive-transcranial-magnetic-stimulation-in-frontotemporal-lobar-degeneration-100617268","NCT07316413","Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration","FTLD_rTMS","Inclusion Criteria:\n\n* diagnosis of FTLD (bvFTD, avPPA, svPPA, CBS, or PSP)\n* global CDR plus NACC FTLD ≤ 1\n\nExclusion Criteria:\n\n* presence of cerebrovascular disease, hydrocephalus, intracranial masses identified by MRI, history of head trauma, serious medical conditions unrelated to FTLD, history of epilepsy, and presence of electronic (e.g., pacemaker) or metallic implants in the head.",{"count":83,"type":20},120,[23],"The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of repetitive transcranial magnetic stimulation (rTMS) in patients with frontotemporal dementia (FTLD) or in asymptomatic persons at risk of FTLD (i.e., persons familiar with FTLD patients).\n\nrTMS is a non-invasive brain stimulation technique, and has demonstrated the ability to modulate neuronal activity by applying high-frequency magnetic fields to the surface of the skull. rTMS offers a potentially effective means to influence neural networks involved in the pathogenesis of neurodegenerative diseases, with benefits that could extend beyond symptomatic relief. Its safety has been widely documented in a variety of clinical conditions, making it an ideal candidate for application in neurodegenerative diseases.\n\nIn the present study, participants will undergo the following procedures: (i) clinical and neuropsychological assessment, (ii) TMS, and (iii) blood sampling. The occurrence of adverse events will be monitored throughout the duration of the study.\n\nThe study is structured in two phases. In the first phase, double-blind, randomised and placebo-controlled, participants will be randomised into two groups: group 1, participants will receive real rTMS for 2 weeks; and group 2, placebo rTMS for 2 weeks. In the second, open-label phase, after 10 weeks, both group 1 and group 2 participants will receive real rTMS for 2 weeks. Each participant will receive a total of 4 weeks of intervention (4 weeks of real stimulation in group 1, or 2 weeks of real stimulation and 2 weeks of placebo stimulation in group 2), with 5 sessions per week (Monday to Friday) lasting approximately 30 minutes each.\n\nVisits will take place at the beginning of the study (T00) and after 2 weeks (T02, end of the first phase), 12 weeks (T12, beginning of the second phase), 14 weeks (T14, end of the second phase), 24 weeks (T24, follow-up). During each visit, participants underwent the following procedures: (i) clinical and neuropsychological assessment, (ii) blood sampling, and (iii) TMS. Specific biomarker analyses will be performed on the blood samples to study the pathophysiological mechanisms of the disease and the effect of the experimental intervention.",[87,88,89,90,91,92,93,27],"FTLD","FTD","bvFTD","PPA","PSP","Cortical Basal Syndrome (CBS)","rTMS","2025-12-18",{"date":96,"type":33},"2026-01-05",{"date":98,"type":33},"2025-02-13",{"date":100,"type":20},"2029-02-01",{"name":102,"class":39},"Università degli Studi di Brescia",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":49,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100601767","explore-the-impacts-of-one-session-and-multiple-session-theta-burst-stimulation-over-cerebellum-in-adults-with-autism-spectrum-disorder-100601767","NCT07114770","Explore the Impacts of One Session and Multiple Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder","Inclusion criteria for autistic adults:\n\n* Autistic adults (≥18 years old), confirmed by Autism Diagnostic Observation Schedule.\n* DSM-5 severity level of ASD: level 1 or level 2\n\nInclusion criteria for typically developing control:\n\n* ≥18 years old without autism spectrum disorder\n\nExclusion criteria for all participants:\n\n* Previous or current severe neurological disorders, especially epilepsy\n* Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension\n* Previous or current severe brain injury\n* Implementation of metal materials such as a pacemaker or medication pump\n* Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder, severe major depressive disorder or substance abuse\n* Pregnancy\n* Intracranial space occupied lesions\n* Previous brain surgery or central nerve system infection\n* Concurrent use of medications which increased the risk of seizure attack\n* Participate in another clinical trial within one month\n* With damaged skin at the stimulated region\n* With multiple sclerosis\n* With large ischemic scars\n* Have experienced sleep disorders during brain stimulation\n* Severe alcoholism\n* Concurrent use of antiepileptic drugs\n* Uncontrollable migraines due to increased intracranial pressure\n* Unsuitable for MRI (e.g. those with claustrophobia)\n* Unsuitable for EEG\n* DSM-5 severity level of ASD: level 3\n* Suicidal ideation within one year\n\nWithdrawal criteria:\n\n* Seizure attack during the study period\n* Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)\n* Extreme agitation or irritability during the study period\n* Participants request\n* Clinical symptoms worsened obviously during study period\n* Start to use antiepileptic drugs during study period\n* Suicidal ideation or self-harm behaviors during study period",{"count":19,"type":20},[23],"This study aims to establish a personalized theta burst stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation, rTMS) protocol considering autistic idiosyncrasy (interindividual variability).",[26,27],"2025-08-08",{"date":115,"type":33},"2025-08-11",{"date":117,"type":33},"2025-07-29",{"date":119,"type":20},"2028-12-31",{"name":38,"class":39},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100578593","theta-burst-stimulation-with-an-8-coil-versus-h1-coil-for-resistant-depression-100578593","NCT06813313","Theta Burst Stimulation With an 8-Coil Versus H1-Coil for Resistant Depression","Randomized Controlled Trial of Two Accelerated Transcranial Magnetic Stimulation Methods in the Treatment of Resistant Depression: Intermittent Theta Burst Stimulation With an 8-Coil Versus H1-Coil","rTBShTBS","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Presenting a major depressive episode according to the DSM-5-TR criteria, occurring as part of major depressive disorder (unipolar depression)\n* The major depressive episode must meet the criteria for treatment resistance, defined by a lack of response to at least two different antidepressant treatments prescribed at an effective dose for a duration of 6 weeks or more\n* Stable treatment for at least 6 weeks\n* Affiliation with a social security system or State Medical Assistance (Aide Médicale d'État)\n* Patient agrees to participate in the study and has signed an informed consent form\n\nExclusion Criteria:\n\n* Presence of a contraindication to TMS: epilepsy, intracranial foreign body, cochlear implant, retinal implant, pacemaker\n* Presence of a bipolar disorder according to DSM-5-TR criteria\n* Presence of catatonic or psychotic features during the current episode\n* Presence of severe psychiatric disorders other than a major depressive episode\n* Presence of neurological disorders\n* Unstable epilepsy\n* Current moderate to severe addiction disorders other than caffeine and\u002For tobacco\n* Current suicidal ideation\n* Use of any brain stimulation treatment (ECT, rTMS, tDCS) for the current episode\n* Pregnancy or breastfeeding\n* Women of childbearing potential without effective contraception\n* Persons under guardianship or legal protection",{"count":130,"type":20},108,[23],"The goal of this clinical trial is to compare response rates after treatment with Figure Eight-Coil TMS versus H-Coil TMS on the prefrontal cortex left dorsolateral, in patients suffering from depression resistant. The main question it aims to answer is:\n\nrTBS (accelerated neuronavigated intermittent Theta Burst Stimulation) is more effective than hTBS (accelerated deep intermittent Theta Burst Stimulation) in the treatment of resistant depression in terms of response rate.?\n\nResearchers will compare Figure Eight-Coil TMS (rTBS) versus H-Coil TMS (hTBS) to see if rTBS is more effective than hTBS.\n\nParticipants will:\n\n* Receive, for each stimulation method, 8 sessions per day spaced 50 minutes apart, over 5 days.\n* Have visit all day of stimulation for checkups and tests.\n* Have a a research MRI before and after treatment.\n* Have follow-up visits at 1 month, 2 months, 3 months, 6 months, and 12 months post-treatment, via teleconsultation.",[134,135,27],"Treatment of Resistant Depression","H1-Coil",[137,135,138,139,140,141],"Resistant Depression","Theta burst stimulation","TMS","Accelerated Transcranial Magnetic Stimulation","Intermittent Theta Burst Stimulation with an 8-Coil versus H1-Coil","NOT_YET_RECRUITING","2025-02-03",{"date":145,"type":33},"2025-02-06",{"date":147,"type":20},"2025-02-16",{"date":149,"type":20},"2028-11-18",{"name":151,"class":39},"Dominique JANUEL"]